Psoriasis Treatment Center of Central New Jersey
Trial Pipeline
Upadacitinib for Prurigo Nodularis
NCT06773403
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
NCT06745999
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839
Taltz in Combination With Enstilar for Psoriasis
NCT04372277
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
NCT04347473
Duobrii in Combination With Biologics
NCT04119102
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03827876
An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
NCT03392337
Tralokinumab for Dupilumab Failures
NCT06773455
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 8 |
Therapeutic Areas
What the Pipeline for Psoriasis Treatment Center of Central New Jersey Shows
According to the ClinicalTrials.gov registry, Psoriasis Treatment Center of Central New Jersey is linked to 9 US clinical trials across every stage of research activity. Of those, 8 studies are currently recruiting — about 89% of the sponsor's indexed portfolio — and 0 are already marked complete, representing roughly 0% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Psoriasis Treatment Center of Central New Jersey reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Psoriasis Treatment Center of Central New Jersey is Psoriasis with 5 linked trials, and 3 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.